Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

High-risk prostate cancer: Outcomes of neurovascular bundle preservation

Key clinical point: Neurovascular bundle (NVB) preservation is not associated with worse clinical outcomes in patients with high-risk and/or locally advanced prostate cancer.

Major finding: For bilateral versus unilateral versus no NVB preservation groups at 120 months after radical prostatectomy (RP), biochemical recurrence-free rates were 62.2% vs. 44.3% vs. 27.1% (P less than .001), metastasis-free survival rates were 83.7% vs. 66.7% vs. 60.3% (P less than .001), and overall survival rates were 91.8% vs. 87.5% vs. 72.3% (P less than .001).

Study details: The study included patients with D'Amico high-risk prostate cancer at RP (n = 4,351) who underwent bilateral (35.7%), unilateral (38.0%), or no NVB preservation (26.3%).

Disclosures: No funding information available. The authors declared no conflicts of interest.


Preisser F et al. Prostate Cancer Prostatic Dis. 2020 Aug 19. doi: 10.1038/s41391-020-00266-4.